CDK4 and cancer: A retrospective chart review of patients with HR+, HER2-negative metastatic BC conducted at a cancer center in Washington reported that the CDK4/6 inhibitor palbociclib was prescribed most frequently in combination of with the aromatase inhibitor letrozole (73.5%) [26].